Immunome, Inc. (IMNM) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $23.18: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 1.33; Below-average business quality.
Immunome is a clinical-stage oncology biotech with varegacestat (Phase 3 RINGSIDE trial met all primary and key secondary endpoints in desmoid tumors; NDA planned Q2 2026), IM-1021 (Phase 1 ROR1 ADC showing objective responses), and IM-3050 (Phase 1 FAP radioligand therapy). No... Read more
Sell if holding. Engine safety override at $23.18: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 1.33; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinevaregacestat10-K Item 1A: 'our NDA for varegacestat, once submitted, may not be approved by the FDA'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.18: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 1.33; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $21.50. Score 5.0/10, moderate confidence.
Take-profit target: $30.60 (+32.4% upside). Prior stop was $21.50. Stop-loss: $21.50.
Concentration risk — Pipeline: varegacestat; Quality below floor (1.7 < 4.0).
Immunome, Inc. trades at a P/E of N/A (forward -10.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover IMNM with a consensus score of 4.3/5. Average price target: $35.
What does Immunome, Inc. do?Immunome is a clinical-stage oncology biotech with varegacestat (Phase 3 RINGSIDE trial met all primary and key...
Immunome is a clinical-stage oncology biotech with varegacestat (Phase 3 RINGSIDE trial met all primary and key secondary endpoints in desmoid tumors; NDA planned Q2 2026), IM-1021 (Phase 1 ROR1 ADC showing objective responses), and IM-3050 (Phase 1 FAP radioligand therapy). No approved products or revenue; accumulated deficit of $728.2M as of Dec 31, 2025.